Galmed Pharmaceuticals
GLMD
18 hedge funds and large institutions have $3.56M invested in Galmed Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
10% less funds holding
Funds holding: 20 → 18 (-2)
40% less capital invested
Capital invested by funds: $5.93M → $3.56M (-$2.37M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$72.5K |
| 2 |
CAD
Craig A. Drill
|
+$54.9K |
| 3 |
Barclays
London,
United Kingdom
|
+$12.7K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$7.84K |
| 5 |
MC
Menta Capital
San Francisco,
California
|
+$1.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$242K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$223K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$88K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$22.5K |
| 5 |
Goldman Sachs
New York
|
-$17.6K |
GLMD Hedge Fund Activity: Q1 2016 in Review
18 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2016, worth a combined $3.56M — down 40% from $5.93M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of GLMD and 3 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Shepherd Kaplan Krochuk, adding an estimated $72.5K. The largest seller was Vanguard Group, exiting entirely with an estimated $242K sold.
- 18 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2016, down from 20 in Q4 2015.
- Funds reported $3.56M of Galmed Pharmaceuticals stock for Q1 2016, down 40% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q1 2016 and 5 closed out, a net change of -2 holders.
- The largest Galmed Pharmaceuticals buyer in Q1 2016 was Shepherd Kaplan Krochuk, an estimated $72.5K added.
- The largest Galmed Pharmaceuticals seller in Q1 2016 was Vanguard Group, an estimated $242K sold.
Based on aggregated 13F filings for Q1 2016.